Anika Therapeutics, Inc.

NasdaqGS ANIK

Anika Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024: -14.62%

Anika Therapeutics, Inc. Return on Capital Employed (ROCE) is -14.62% for the Trailing 12 Months (TTM) ending September 30, 2024, a -38.27% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Anika Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2023 was -10.57%, a -80.05% change year over year.
Anika Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2022 was -5.87%, a -52.15% change year over year.
Anika Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2021 was -3.86%, a -1,335.94% change year over year.
Anika Therapeutics, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2020 was 0.31%, a -97.68% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGS: ANIK

Anika Therapeutics, Inc.

CEO	Dr. Cheryl Renee Blanchard Ph.D.
IPO Date	May 3, 1993
Location	United States
Headquarters	32 Wiggins Avenue
Employees	357
Sector	Health Care
Industries Pharmaceuticals

Description

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Key trends

Past 5 years